Skip to content
Boost Up Blog – Lifestyle
Author:
Actuate Therapeutics
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
June 9, 2026
Over 40% of Western and Australian Tourists Try Beauty Services in Japan, Survey Finds
May 28, 2026
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
April 15, 2026
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
March 9, 2026
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
March 5, 2026